Saturday 17 October 2026
Export PLSE’s income statement to Excel — free account
Pulse Biosciences, Inc
PLSE Healthcare Medical Instruments & Supplies
Pulse Biosciences, Inc’s revenue for fiscal 2025 (year ended December 2025) was $350,000.00, down 50.0% from fiscal 2022. In the quarter to June 2026, revenue grew 4,922.2%, EPS fell 28.6% and free cash flow fell 45.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
44.27
1.32
−2.90%
Follow PLSE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1,619.34 | 1,978.44 | 1,526.95 | 1,517.45 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(102.57) | (100.58) | (62.71) | (91.47) | |
P/B ratio |
19.29 | 22.14 | 11.47 | 12.87 | |
Price to Tangible BV |
19.89 | 23.27 | 11.97 | 13.38 | |
EV/Sales |
1,589.11 | 1,975.05 | 1,502.31 | 1,480.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(30.82) | (26.55) | (16.82) | (23.98) | |
EV/FCF |
(30.68) | (26.41) | (16.72) | (23.85) | |
Quick Ratio |
9.27 | 6.99 | 10.22 | 9.82 | |
Current Ratio |
9.63 | 7.26 | 10.53 | 10.02 | |
Net Debt/EBITDA |
4.06 | 3.62 | 4.49 | 4.73 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.76 | 0.79 | 0.85 | 0.67 | |
Capex/Depreciation |
(0.35) | (0.13) | (0.41) | (0.24) | |
Research and Development Expense of Revenue |
3,911.52% | 3,139.65% | 4,139.02% | 13,247.67% | |
Selling, General and Administrative Expense of Revenue |
1,948.62% | 1,643.64% | 2,776.52% | 10,210.47% | |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.04 | 0.03 | |
Share Based Compensation of Revenue |
1,145.85% | 476.81% | 1,882.58% | 6,531.40% | |
Graham Net Nets |
0.05 | 0.04 | 0.08 | 0.07 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(4.26%) | (5.09%) | (7.87%) | (6.38%) | |
Free Cash Flow Yield |
(3.20%) | (3.78%) | (5.88%) | (4.09%) | |
Revenue per Share |
0.01 | 0.01 | 0.00 | 0.00 | |
Operating CF per Share |
(0.27) | (0.21) | (0.22) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.27) | (0.22) | (0.22) | (0.19) | |
Cash per Share |
1.47 | 1.00 | 1.20 | 1.41 | |
Shareholders Equity per Share |
1.44 | 0.98 | 1.20 | 1.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.44 | 0.98 | 1.20 | 1.38 | |
Free Cash Flow |
(18.80) | (14.63) | (14.86) | (13.10) | |
Working Capital |
94.72 | 61.33 | 75.50 | 87.46 | |
Capital Expenditures |
(0.09) | (0.03) | (0.10) | (0.06) | |
Net Current Asset Value |
89.64 | 55.81 | 69.54 | 81.09 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.21 | 0.08 | 0.40 | 0.72 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.06 | 0.08 | 0.15 | 0.04 | |
Average Payables |
2.79 | 2.57 | 2.23 | 2.35 | |
Average Inventory |
0.14 | 0.12 | 0.44 | 3.96 | |
Average Assets |
117.91 | 107.50 | 113.50 | 100.91 | |
Average Common Equity |
101.99 | 92.38 | 97.76 | 85.91 |
Columns are period end dates